NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Appoints Senior Vice President of U.S. Sales

SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the appointment of Jeffrey Rydin to the newly created position of Senior Vice President, U.S. Sales. Mr. Rydin, who joins NuVasive from DePuy Spine, Inc., will be responsible for the Company's U.S. sales efforts, including the oversight of strategic sales development, sales administration, divisional sales directors and sales training. He will also serve as a member of NuVasive's Executive Management Committee.

Prior to joining NuVasive, Mr. Rydin was Area Vice President at DePuy Spine, Inc. a global designer, manufacturer, and supplier of spinal devices and subsidiary of Johnson & Johnson. His responsibilities at the firm during his three-year tenure included building the DePuy sales team in the Southeastern U.S.

Mr. Rydin has a vast degree of successful sales experience coupled with performance-based promotions from initially Xerox, US Surgical, and Baxter to senior management experience at General Surgical Innovations, Symphonix, Orquest and most recently DePuy Spine. He has a track record of building dynamic and highly successful sales teams. He received a B.A. degree in Social Ecology from the University of California, Irvine.

Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "Jeff Rydin's experience as an orthopedic sales executive, with a proven ability to create and lead successful and dynamic sales teams, will be a tremendous asset to NuVasive. We believe his background and extensive knowledge of the spine industry will allow him to seamlessly integrate into this new role. Jeff will focus on further strengthening our direct sales team of Area Business Managers and Spine Specialists as we continue to make rapid progress on the creation of a hybrid sales force consisting of direct sales employees and exclusive, independent distributors. Jeff will be a prime example of Absolute Responsiveness(TM), which defines our culture of striving to provide the utmost in service and responsiveness to our customers. I am confident that Jeff will lead our team to maximum performance for many years to come."

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.

MAS combines three categories of current product offerings -- NeuroVision(R), a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(TM) -- that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR) and a nucleus-like cervical disc replacement.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive may be unable to successfully integrate new products or technologies into its business; the risk that additional clinical experience may demonstrate that NuVasive's products do not provide the intended safe and reproducible results; risks related to NuVasive's ability to effectively manage the growth of its business; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                            Investors:
     Kevin C. O'Boyle                   Stephanie Carrington/Nick Laudico
     EVP & Chief Financial Officer      The Ruth Group
     NuVasive, Inc.                     646-536-7017/7030
     858-909-1800                       scarrington@theruthgroup.com
     investorrelations@nuvasive.com     nlaudico@theruthgroup.com

SOURCE
NuVasive, Inc.
12/06/2005